Mark Schoenebaum - Bloomberg

MARK SCHOENEBAUM

Related Articles

Bristol-Myers Drug Cocktail Stymies Melanoma Tumors
6 days ago

Lilly Stops Trial of Lymphoma Drug Due to Ineffectiveness
12 days ago

Gilead Misses Analysts’ Estimates on Sales of HIV Drugs
1 months ago

Gilead’s Hepatitis C Treatment Clears Virus in Eight Weeks
1 months ago

Actavis Seen Selling for Higher Valuation: Real M&A
1 months ago

Merck Cuts Profit Forecast as Buyback Boosted $15 Billion
1 months ago

Pfizer Lowers 2013 Forecast After Sales Miss Estimates
1 months ago

Biogen MS Pill’s Early Sales May Help It Beat Estimates
1 months ago

Pfizer’s Arthritis Drug Rejected by European Regulators
1 months ago

Biogen Raises 2013 Forecast After First-Quarter Profit Surges
1 months ago

Eli Lilly Profit Beats Estimates on Lower Costs
1 months ago

Pfizer’s Read Finds Reason to Keep Consumer Health Unit
2 months ago

Gilead Hits Record High on Analyst’s View of Higher Sales
2 months ago

S&P 500 Falls After 7-Day Rally Drove Index Toward Record
2 months ago

Merck Gains on Plans to Continue With Cholesterol Study
2 months ago

Celgene Psoriasis Drug Helped Third of Patients in Study
3 months ago

Zoetis Plans to Keep Factories as It Seeks New Products
4 months ago

Pfizer’s Zoetis Surges in Trading After $2.24 Billion IPO
4 months ago

Bristol-Myers Tops Profit Estimates on Tax Benefit
4 months ago

Pfizer’s Possible Unit Shuffle Triggers Breakup Concern
4 months ago

Show More News

TOOLS
Watchlist | Stock Finder | Saved